Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: Implications for lymphatic transport and absolute bioavailability studies

Journal of Pharmaceutical Sciences

Volumn 101, Issue 9, 2012, Pages 3540-3546

  Caliph, Suzanne M ^a   Trevaskis, Natalie L ^a   Charman, William N ^a   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Bioavailability; Clearance; Formulation; Intravenous; Lipid; Lipophilic drug; Lipoproteins; Lymph; Lymphatic transport; Volume of distribution

Indexed keywords

HALOFANTRINE; LIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG TRANSPORT; EMULSION; EX VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIPID BLOOD LEVEL; LIPOPHILICITY; LYMPHATIC SYSTEM; NONHUMAN; PLASMA; RAT;

EID: 84864063727     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23211     Document Type: Article

References (37)

1. Trevaskis NL, Charman WN, Porter CJH. 2008. Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update. Adv Drug Deliv Rev 60(6):702-716.
2. Porter CJH, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6(3):231-248.
3. Charman WN, Noguchi T, Stella VJ. 1986. An experimental system designed to study the in situ intestinal lymphatic transport of lipophilic drugs in anaesthetised rats. Int J Pharm 33:155-164.
4. Gershkovich P, Hoffman A. 2005. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: Linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci 26(5):394-404.
5. Trevaskis NL, McEvoy CL, McIntosh MP, Edwards GA, Shanker RM, Charman WN, Porter CJH. 2010. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524, 515 and CP532, 623). Pharm Res 27(5):878-893.
6. Trevaskis NL, Shanker RM, Charman WN, Porter CJH. 2010. The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524, 515 and CP532, 623) and evaluation of their impact on lymph lipoprotein profiles. Pharm Res 27(9):1949-1964.
7. Sieber SM, Cohn VH, Wynn WT. 1974. The entry of foreign compounds into the thoracic duct lymph of the rat. Xenobiotica 4:265-284.
8. Porter CJH, Charman SA, Charman WN. 1996. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: Effect of lipid vehicle dispersion. J Pharm Sci 85(4):351-356.
9. Porter CJH. 1997. Drug delivery to the lymphatic system. Crit Rev Ther Drug Carrier Syst 14(4):333-393.
10. Hauss DJ, Mehta SC, Radebaugh GW. 1994. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid regulator drug. Int J Pharm 108:85-93.
11. Brocks DR, Ala S, Aliabadi HM. 2006. The effects of increased lipoprotein levels on the pharmacokinetics of Cyclosporine A in the laboratory rat. Biopharm Drug Dispos 27:7-16.
12. Wasan KM, Brocks DR, Lee SD, Sachs-Barrable K, Thornton SJ. 2008. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: Implications for drug discovery. Nat Rev Drug Discov 7(1):84-99.
13. Gershkovich P, Hoffman A. 2007. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: The importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci 32(1):24-32.
14. Caliph SM, Charman WN, Porter CJH. 2000. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 89(8):1073-1084.
15. Holm R, Porter CJH, Mullertz A, Kristensen HG, Charman WN. 2002. Structured triglyceride vehicles for oral delivery of halofantrine: Examination of intestinal lymphatic transport and bioavailability in conscious rats. Pharm Res 19(9):1354-1361.
16. Porter CJH, Charman SA, Humberstone AJ, Charman WN. 1996. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: Effect of lipid class and lipid vehicle dispersion. J Pharm Sci 85(4):357-361.
17. Charman WN, Porter CJH. 1999. Halofantrine free base for the treatment of malaria and compositions. United States Patent Documents. ed., United States; Bedford, United Kingdom: SmithKline Beecham p.I.c, pp 1-9.
18. Edwards GA, Porter CJH, Caliph SM, Khoo SM, Charman WN. 2001. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev 50(1-2):45-60.
19. Humberstone AJ, Currie GJ, Porter CJH, Scanlon MJ, Charman WN. 1995. A simplified liquid chromatography assay for the quantitation of halofantrine and desbutylhalofantrine in plasma and identification of a degradation product of desbutylhalofantrine formed under alkaline conditions. J Pharm Biomed Anal 13:265-272.
20. Baune B, Flinois JP, Furlan V, Gimenez F, Taburet AM, Becquemont L, Farinotti R. 1999. Halofantrine metabolism in microsomes in man: Major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol 51(4):419-426.
21. Khoo SM, Porter CJH, Edwards GA, Charman WN. 1998. Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole. J Pharm Sci 87(12):1538-1541.
22. Gharavi N, Sattari S, Shayeganpour A, El-Kadi AOS, Brocks DR. 2007. The stereoselective metabolism of halofantrine to desbutylhalofantrine in the rat: Evidence of tissue-specific enantioselectivity in microsomal metabolism. Chirality 19(1):22-33.
23. Brocks DR, Wasan KM. 2002. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J Pharm Sci 91(8):1817-1826.
24. Humberstone AJ, Porter CJH, Edwards GA, Charman WN. 1998. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J Pharm Sci 87(8):936-942.
25. Patel JP, Fleischer JG, Wasan KM, Brocks DR. 2009. The effect of experimental hyperlipidemia on the stereoselective tissue distribution, lipoprotein association and microsomal metabolism of (+/-)-halofantrine. J Pharm Sci 98(7):2516-2528.
26. Shayeganpour A, Korashy H, Patel JP, El-Kadi AO, Brocks DR. 2008. The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 361(1-2):78-86.
27. McIntosh MP, Porter CJH, Wasan KM, Ramaswamy M, Charman WN. 1999. Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipoprotein lipid. J Pharm Sci 88(3):378-384.
28. Ferezou J, Bach AC. 1999. Structure and metabolic fate of triacylglycerol- and phospholipid-rich particles of commercial parenteral fat emulsions. Nutrition 15(1):44-50.
29. Robinson SF, Quarfordt SH. 1979. Apoproteins in association with Intralipid incubations in rat and human plasma. Lipids 14(4):343-349.
30. Weinberg RB, Scanu AM. 1982. In vitro reciprocal exchange of apoproteins and nonpolar lipids between human high density lipoproteins and an artificial triglyceride-phospholipid emulsion (Intralipid). Atherosclerosis 44(2):141-152.
31. Caliph SM, Fried Faassen WA, Vogel GM, Porter CJH. 2009. Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues. Curr Drug Deliv 6(4):359-366.
32. Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Hisaoka M. 1996. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol Pharm Bull 19(2):252-258.
33. Lundberg BB, Risovic V, Ramaswamy M, Wasan KM. 2003. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release 86(1):93-100.
34. Su J, Zhang N, Ho PC. 2008. Evaluation of the pharmacokinetics of all-trans-retinoic acid (ATRA) in Wistar rats after intravenous administration of ATRA loaded into tributyrin submicron emulsion and its cellular activity on caco-2 and HepG2 cell lines. J Pharm Sci 97(7):2844-2853.
35. Hamdy DA, Brocks DR. 2011. Effect of hyperlipidemia on ketoconazole-midazolam drug-drug interaction in rat. J Pharm Sci 100(11):4986-4992.
36. Lee JH, Oh JH, Lee YJ. 2011. Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats. Xenobiotica 41(9):797-804.
37. Wojcicki J, Sulzyc-Bielicka V, Kutrzeba J, Gawronska-Szklarz B, Drozdzik M, Sterna Z. 1999. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. J Clin Pharmacol 39(8):826-833.